Suppr超能文献

针对 HIV-1 gp120 的 CD4 结合位点的强效抗体的种系基因使用的结构基础。

Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120.

机构信息

Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA.

出版信息

Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):E2083-90. doi: 10.1073/pnas.1208984109. Epub 2012 Jun 27.

Abstract

A large number of anti-HIV-1 antibodies targeting the CD4-binding site (CD4bs) on the envelope glycoprotein gp120 have recently been reported. These antibodies, typified by VRC01, are remarkable for both their breadth and their potency. Crystal structures have revealed a common mode of binding for several of these antibodies; however, the precise relationship among CD4bs antibodies remains to be defined. Here we analyze existing structural and sequence data, propose a set of signature features for potent VRC01-like (PVL) antibodies, and verify the importance of these features by mutagenesis. The signature features explain why PVL antibodies derive from a single germ-line human V(H) gene segment and why certain gp120 sequences are associated with antibody resistance. Our results bear on vaccine development and structure-based design to improve the potency and breadth of anti-CD4bs antibodies.

摘要

大量针对包膜糖蛋白 gp120 上的 CD4 结合位点 (CD4bs) 的抗 HIV-1 抗体最近已经被报道。这些抗体,以 VRC01 为代表,其特点是具有广谱性和高效性。晶体结构揭示了其中几种抗体的一种共同结合模式;然而,CD4bs 抗体之间的确切关系仍有待确定。在这里,我们分析了现有的结构和序列数据,提出了一组强效 VRC01 样 (PVL) 抗体的特征,并通过突变来验证这些特征的重要性。这些特征解释了为什么 PVL 抗体来源于单一的人类 V(H) 基因片段,以及为什么某些 gp120 序列与抗体耐药性相关。我们的研究结果对疫苗开发和基于结构的设计具有重要意义,有助于提高抗 CD4bs 抗体的效力和广谱性。

相似文献

1
Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120.
Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):E2083-90. doi: 10.1073/pnas.1208984109. Epub 2012 Jun 27.
2
Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
J Virol. 2012 May;86(10):5844-56. doi: 10.1128/JVI.07139-11. Epub 2012 Mar 14.
3
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.
Science. 2010 Aug 13;329(5993):811-7. doi: 10.1126/science.1192819. Epub 2010 Jul 8.
4
Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody.
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6049-54. doi: 10.1073/pnas.1303682110. Epub 2013 Mar 22.
8
Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site.
JCI Insight. 2018 Mar 8;3(5):97018. doi: 10.1172/jci.insight.97018.
9
Increasing the potency and breadth of an HIV antibody by using structure-based rational design.
Science. 2011 Dec 2;334(6060):1289-93. doi: 10.1126/science.1213782. Epub 2011 Oct 27.

引用本文的文献

2
Structural insights into VRC01-class bnAb precursors with diverse light chains elicited in the IAVI G001 human vaccine trial.
Proc Natl Acad Sci U S A. 2025 Aug 19;122(33):e2510163122. doi: 10.1073/pnas.2510163122. Epub 2025 Aug 11.
3
Priming VRC01-precursor B cells with non-envelope immunogens disfavors boosting with HIV-1 envelope.
NPJ Vaccines. 2025 Aug 5;10(1):185. doi: 10.1038/s41541-025-01235-5.
4
In vivo antibody diversification targeting a conserved coronavirus epitope.
J Exp Med. 2025 Oct 6;222(10). doi: 10.1084/jem.20241563. Epub 2025 Jul 17.
5
Low nanomolar affinity to major grass pollen allergen Phl p 5 as achieved in an unmutated human antibody-lineage ancestor.
Front Immunol. 2025 Jul 1;16:1600778. doi: 10.3389/fimmu.2025.1600778. eCollection 2025.
6
Transient glycan shield reduction induces CD4-binding site broadly neutralizing antibodies in SHIV-infected macaques.
Cell Rep. 2025 Jun 24;44(6):115848. doi: 10.1016/j.celrep.2025.115848. Epub 2025 Jun 13.
8
Increased immunogen valency improves the maturation of vaccine-elicited HIV-1 VRC01-like antibodies.
PLoS Pathog. 2025 May 29;21(5):e1013039. doi: 10.1371/journal.ppat.1013039.
9
Mapping essential somatic hypermutations in a CD4-binding site bNAb informs HIV-1 vaccine design.
Cell Rep. 2025 May 27;44(5):115713. doi: 10.1016/j.celrep.2025.115713. Epub 2025 May 15.
10
Increased immunogen valency improves the maturation of vaccine-elicited HIV-1 VRC01-class antibodies.
bioRxiv. 2025 Mar 14:2025.03.13.642975. doi: 10.1101/2025.03.13.642975.

本文引用的文献

1
Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
J Virol. 2012 May;86(10):5844-56. doi: 10.1128/JVI.07139-11. Epub 2012 Mar 14.
3
Increasing the potency and breadth of an HIV antibody by using structure-based rational design.
Science. 2011 Dec 2;334(6060):1289-93. doi: 10.1126/science.1213782. Epub 2011 Oct 27.
4
Progress in the rational design of an AIDS vaccine.
Philos Trans R Soc Lond B Biol Sci. 2011 Oct 12;366(1579):2759-65. doi: 10.1098/rstb.2011.0096.
5
Broad neutralization coverage of HIV by multiple highly potent antibodies.
Nature. 2011 Sep 22;477(7365):466-70. doi: 10.1038/nature10373.
6
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.
Science. 2011 Sep 16;333(6049):1593-602. doi: 10.1126/science.1207532. Epub 2011 Aug 11.
7
High-resolution description of antibody heavy-chain repertoires in humans.
PLoS One. 2011;6(8):e22365. doi: 10.1371/journal.pone.0022365. Epub 2011 Aug 4.
8
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.
Science. 2011 Sep 16;333(6049):1633-7. doi: 10.1126/science.1207227. Epub 2011 Jul 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验